Join Our Mailing List

Your Name: 

Your Email:  

 
  • Embera NeuroTherapeutics, Inc. Closes Series A Funding

    February 27th, 2007 No comments

    Embera NeuroTherapeutics, Inc., a start-up company developing novel treatments for a broad range of addictions, as well as other neuropsychiatric disorders, has secured over $800,000 of Series A financing that will help the company move its novel combinational drug into Phase 1b FDA trials.

    Embera NeuroTherapeutics is based on technology discovered by Dr. Nicholas Goeders at the Louisiana State University Health Sciences System in Shreveport.

    Embera NeuroTherapeutics, Inc. is funded by Louisiana Ventures, LP, and is dedicated to freeing minds from diseases such as addiction, depression, anxiety disorders and related diseases. While initially targeting cocaine addiction, the company is developing novel treatments for a broad range of addictions, including nicotine, methamphetamine (“crystal meth”) and alcohol addiction, as well as other neuropsychiatric disorders.

    Board member and President Marie A. Lindner, M.D. said, “By targeting the specific Brain functions associated with stress, Embera stands as one of the first companies to provide possible preventive as well as therapeutic treatments for drug and alcohol abuse, as well as treatments for a host of other mental illnesses.”

    “Like most scientific breakthroughs, this technology came from years of research,” said Ross P. Barrett, managing partner of Louisiana Ventures, LP. “Standing on the strength of 20 years of research from Dr. Goeders, coupled with the capitalization and seasoned, life-science focused Board of Directors we have compiled, the company is now poised for the Phase 1b FDA trials.”

    While most other medicines designed to treat drug and alcohol addictions typically only target the limbic system of the brain, Embera’s approach targets the prefrontal cortex, which is a higher cognitive center than the limbic system. Embera’s lead therapeutic patent-pending drug, EMB 001, developed by Dr. Goeders, is a novel composition of two off-patent, FDA-approved drugs with a long history of use and an established safety profile.

    Embera will use the Series A funding to perform clinical trials and research to support additional indications.

    “Louisiana Fund I has followed the development of this technology at LSU Health Sciences Center for several years and we are very excited about the potential of a breakthrough in addiction treatment that could come from this technology,” said Joseph F. Lovett, managing general partner of Louisiana Fund I. “We are delighted to have Embera located in Shreveport. Also, we are looking forward to working with board members Dr. Marie Lindner and Dr. Franz F. Hefti who are highly experienced at operational execution in the biomedical area.”

    As part of the financing, Joe Lovett and Dr. Franz Hefti joined the Embera board of directors.

    For more information, please visit: www.emberaneuro.com

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 1,330 bad guys.

 

Latest Headlines:

Saturday July 24, 2010
Investors Show Interest in Trillion Dollar Outdoor Lifestyles Industry as NBFog Closes Bridge Funding Round


Thursday July 22, 2010
Euthymics Biosciences Closes $24 Million in Series A Funding and Acquires DOV Pharmaceutical


Thursday July 22, 2010
MK Capital Leads $8 Million in Series C Funding for TopSchool


Wednesday July 21, 2010
NGP Energy Technology Partners Leads Undisclosed Dollar Amount in Series D Funding Round for LedEngin


Tuesday July 20, 2010
Santé Ventures Leads $6 Million in Series B Funding for EndoStim


Friday July 16, 2010
Round Table Healthcare Partners Closes $600 Million Equity Fund and $200 Million Capital Fund


Friday July 16, 2010
Trilliant Raises $106 Million in Growth Capital, Funding Round Led by Investor Growth Capital, Vantage Point, ABB, and GE


Thursday July 15, 2010
Polaris Venture Partners and New Enterprise Associates Lead $35 Million in Series B Funding for Travena


 

Bad Behavior has blocked 382 access attempts in the last 7 days.